EMJ GOLD

The UK will hike statutory payment rates for branded drugs to over 30% in 2025, far surpassing other European markets and raising concerns.

According to new research from the ABPI, pharma companies need to modernise their outreach strategies.

Vantive has announced the five-year, major investment to expand its R&D and manufacturing capabilities.

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

The King’s Fund in the UK has released an updated explainer on the availability of new medicines in the UK’s NHS.

The Paris biotech aims to improve biologic drugs by mastering glycan control, aiming for safer, more effective therapies.

Catch up on May’s key pharma news, research updates and policy shifts.

BioNTech is set to invest up to £1bn in the UK over the next decade, establishing new R&D and AI hubs.

Experts have pointed to the climate crisis as a potential trigger of the West Nile Virus finding.

Dr Tedros sets out WHO’s next steps on pandemic preparedness, climate action and AMR during the 78th World Health Assembly in Geneva.

Colorectal cancer now has the most real-world data, but Phesi warns clinical trials are lagging behind.

WHAM’s Innovator’s Circle unites top funds to address the women’s health investment gap.

Trump’s “most-favoured nation” drug pricing plan shakes pharma markets, sparking losses for US and EU firms.

The initiative is set to revolutionise healthcare delivery and agricultural exports in low- and middle-income countries.

Gallman takes on the role of EVP, General Counsel and Chief Policy Officer, following Sandra Leung’s retirement after 33 years.

From new scientific data-sharing initiatives to US drug tariffs, May brought a range of major news to the pharma landscape.

Eli Lilly joins forces with Alchemab in a deal worth $415m, expanding its neuroscience pipeline with a novel candidate.

Generation Gold Standard is a universal vaccine platform targeting influenza, coronaviruses and future pandemics.

Novartis announces acquisition of Regulus Therapeutics, adding a potential first-in-class miR-17 inhibitor to its renal pipeline.

ViiV leads the 2024/25 pharma company reputation rankings, with the PatientView report also finding ways to improve.

Ireland has launched its first national clinical genomics study in paediatric oncology.

Boehringer Ingelheim and Tessellate Bio form a €500m partnership to develop precision therapies.

US drug tariffs may not hit branded prices hard, but generics and supply chains face disruption. Here’s what pharma leaders need to know.

FluidForm Bio’s 3D bioprinting tech keeps lab-grown cells alive five times deeper using vascular-like gelatin scaffolds.

The UK government has formally signed into law new clinical trial regulations, designed to modernise operations across the country.

CloudSpec speeds up lipid nanoparticle analysis, cutting lab times from hours to seconds for gene therapy and vaccine research.

The UK government has announced a significant new initiative to accelerate drug discovery and improve patient care in the country.  

Pharma must balance creativity with transparency to rebuild trust in 2025. VML Health’s report reveals key trends shaping expectations.

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an expanded role.

From the latest news impacting the UK’s NHS to large industry acquisitions, March brought a range of impactful news.

Discover the latest pharma innovations, from needle-free vaccines to NHS data access and interactive case studies in medical education.

A gene therapy for heart failure with preserved ejection fraction (HFpEF) has shown promising early results.

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

A new study is challenging the belief that dementia is incompatible with modern work environments, with AI helping employees stay in work.

The biopharmaceutical industry’s return on investment in innovation is increasing, but R&D costs are rising, according to a new Deloitte report.

The industry already contributes more than £17.6 billion directly to the UK economy, but it believes that growth has stagnated because of VPAG.

Pfizer has announced plans to sell its remaining stake in Haleon plc, divesting approximately 662 million shares.

AstraZeneca has announced a $1bn agreement to acquire EsoBiotec, a Belgian biotech firm pioneering in vivo cell therapies.

The NICE has approved the first daily oral treatment for endometriosis symptoms for use within the NHS in England.

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.